CybeRelease: Philippines Company to Import Amazon Biotech’s AIDS Drug
(CybeRelease, November 14, 2006) - Lake Harmony, PA - Amazon Biotech, Inc. (OTC BB: AMZB) (Frankfurt: B2D.F) today announced that its distributor in the Philippines, Union Bless Herbal Products, is applying for an amendment to its current approved drug import license, in order to include Amazon as an approved supplier.
BFAD, the Philippines Bureau of Food and Drugs, is the governmental body responsible for granting import licenses for foods and drugs into the Philippines. Union Bless Herbal Products has been granted such a license for natural drug therapies, and now is adding Amazon Biotech to that license for the importation of AMZ0026, Amazon Biotech’s therapeutic herbal composition and primary drug candidate for HIV/AIDS.
Although it does not imply approval for distribution, receiving this import license is the first step to conduct clinical trials in that country. AMZ0026 is currently under Investigational New Drug (IND) status by the US FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
For a Free Newsletter and more information, go to http://www.OTCReporter.com.
To read the complete release, go to http://biz.yahoo.com/iw/061114/0183687.html.
CybeRelease Gainers are GeoPharma, Inc. (Nasdaq: GORX), Movie Gallery, Inc. (Nasdaq: MOVI), IONA Technologies PLC (Nasdaq: IONA), TiVo Inc. (Nasdaq: TIVO), Coldwater Creek, Inc. (Nasdaq: CWTR), Siliconware Precision Industries Company, Ltd. (Nasdaq: SPIL), EntreMed, Inc. (Nasdaq: ENMD) and Golf Galaxy, Inc. (Nasdaq: GGXY).
CybeRelease Decliners are Mamma.com Inc. (Nasdaq: MAMA), Fossil, Inc. (Nasdaq: FOSL), Eagle Bulk Shipping Inc. (Nasdaq: EGLE), Jaco Electronics, Inc. (Nasdaq: JACO), Qiagen N.V. (Nasdaq: QGEN), China TechFaith Wireless Communication Technology Limited (Nasdaq: CNTF), IRIS International, Inc. (Nasdaq: IRIS) and Staples, Inc. (Nasdaq: SPLS).
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A Third Party has hired and paid $500.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.
- Contact Information
- C. P. Barry
- Media Contact
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.